Merus BV of the Netherlands has announced the appointment of Setareh van Driel Shamsili as chief medical officer to help direct the company’s oncology drug development programme. Merus has a bispecific antibody platform. Dr van Driel Shamsili joins Merus from Astellas Pharma where she was global medical leader in oncology. She is a medical doctor and also holds a PhD in neuro-oncology from Erasmus University in Rotterdam.
Merus announced the appointment on 11 December 2012.
Copyright 2012 Evernow Publishing Ltd.